Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David-Erick Lafontant

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Parkinsonism & Related Disorders|October 17, 2021
Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's diseaseAlberto J Espay, David-Erick Lafontant, Kathleen L Poston, et al.
Medrxiv : the Preprint Server for Health Sciences|October 17, 2024
Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson's DiseasePaulina Gonzalez-Latapi, Caroline Gochanour, Hyunkeun Cho, et al.
Journal of Clinical and Translational Science|September 22, 2025
Community engagement strategies improve recruitment and enrollment in a pragmatic clinical trialKari G Vance, Jonah Pedelty, Barbara J Van Gorp, et al.
Annals of Clinical and Translational Neurology|March 11, 2026
Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's DiseasePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
JAMA Neurology|December 14, 2020
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical TrialTanya Simuni, Brian Fiske, Kalpana Merchant, et al.
Acta Neuropathologica Communications|November 7, 2021
High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's diseaseMarco J Russo, Christina D Orru, Luis Concha-Marambio, et al.
Physical Therapy|August 29, 2022
The Fibromyalgia Transcutaneous Electrical Nerve Stimulation in Physical Therapy Study Protocol: A Multisite Embedded Pragmatic TrialAndrew A Post, Dana L Dailey, Emine O Bayman, et al.
Annals of Neurology|May 19, 2026
Outcomes in Long-Term Follow-Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers InitiativePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
Annals of Clinical and Translational Neurology|April 22, 2026
Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined SynucleinopathyDaniel Weintraub, Michele K York, Roseanne Dobkin, et al.
Brain Communications|March 21, 2025
<i>LRRK2</i>-associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Parkinsonism & Related Disorders|October 17, 2021
Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's diseaseAlberto J Espay, David-Erick Lafontant, Kathleen L Poston, et al.
Medrxiv : the Preprint Server for Health Sciences|October 17, 2024
Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson's DiseasePaulina Gonzalez-Latapi, Caroline Gochanour, Hyunkeun Cho, et al.
Journal of Clinical and Translational Science|September 22, 2025
Community engagement strategies improve recruitment and enrollment in a pragmatic clinical trialKari G Vance, Jonah Pedelty, Barbara J Van Gorp, et al.
Annals of Clinical and Translational Neurology|March 11, 2026
Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's DiseasePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
JAMA Neurology|December 14, 2020
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical TrialTanya Simuni, Brian Fiske, Kalpana Merchant, et al.
Acta Neuropathologica Communications|November 7, 2021
High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's diseaseMarco J Russo, Christina D Orru, Luis Concha-Marambio, et al.
Physical Therapy|August 29, 2022
The Fibromyalgia Transcutaneous Electrical Nerve Stimulation in Physical Therapy Study Protocol: A Multisite Embedded Pragmatic TrialAndrew A Post, Dana L Dailey, Emine O Bayman, et al.
Annals of Neurology|May 19, 2026
Outcomes in Long-Term Follow-Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers InitiativePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
Annals of Clinical and Translational Neurology|April 22, 2026
Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined SynucleinopathyDaniel Weintraub, Michele K York, Roseanne Dobkin, et al.
Brain Communications|March 21, 2025
<i>LRRK2</i>-associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Pageof 3